Animal study demonstrating CBD’s (cannabidiol) effects on neuroplasticity and memory loss

Virginia Thornley, M.D.
Neurologist, Epileptologist
August 26, 2019
In an animal study, one group demonstrates that Cannabidiol may help with the neuroplasticity in patients with Alzheimer’s disease (1).
LTP in the hippocampus is the long-term potentiation seen that elevates the efficacy of synapses involved in memory. Beta-amyloid peptide is toxic towards this  feature. When animals were pretreated with CBD the neurotoxicity was found to be reduced against beta-amyloid peptide. The same study showed that it did not involve the 5-HT1a, CB1 or adenosine receptors (1).
There have been other previous studies showing that cannabidiol could have protective effects against the toxic effects of beta-amyloid peptide which is involved in the neurodegenerative process seen in Alzheimer’s disease.
More clinical randomized control trials are needed. Animal studies do not always translate into human studies.
  1. Hughes, B., Herron, C.E., Cannabidiol reverses deficits in hippocampal LTP in a model of Alzheimer’s disease. Neurochem. Res. 2019, Mar. 44(3):703-713

This is medical information not medical advice. Please consult with your physician.


Can anti-cholinergics cause dementia?

Can anti-cholinergics cause dementia?
Virginia Thornley, M.D., Neurologist, Epileptologist
July 1, 2019
In one study, they found that anti-cholinergic agents shows an increased risk of dementia. In the study, certain anti-depressants and urologic agents were found to correlate more with the risk of dementia including dosulepine, duloxetine and amitriptyline for the anti-depressants and tolteridine and oxybutinin for the urologic agents (1).
There are thoughts that there is a risk of dementia even 2 decades after the exposure. Certain anti-Parkinson’s agents were found to possible correlate with dementia. Anti-cholinergic agents have consistently been associated with problems with short-term memory.
1.Richardson, K., Fox, C., Maidment, I, Steel, N., Loke, Y, Arthur, A., Myint, P., Grossi, C., Mattishent, K., Bennett, K., Campbell, N., Boustani, M., Robinson, L., Brayne, C., Matthews, F., Savva, G. Anti-cholinergic drugs and risk of dementia: case-control study, BMJ, 2018; 361